Irvine Clinical Research | Irvine, CA
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptomatic Alzheimer's disease (AD) and explore participant characteristics that might predict risk of ARIA.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Exceptions:
non-metastatic basal- or squamous-cell skin cancer
Stage 0 non-invasive carcinoma of the cervix
Stage 0 non-invasive prostate cancer, or
other cancers with low risk of recurrence or spread
Primary purpose
Allocation
Interventional model
Masking
800 participants in 4 patient groups
Loading...
Central trial contact
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal